Brain perfusion SPECT imaging and acetazolamide challenge in vascular cognitive impairment

Nuclear Medicine Communications

Volumn 33, Issue 6, 2012, Pages 571-580

  Farid, Karim ^a,f   Petras, Slavomir ^b   Ducasse, Valérie ^a   Chokron, Sylvie ^c   Helft, Gérard ^d   Blacher, Jacques ^a,b,e   Caillat Vigneron, Nadine ^a,e  

^a HÔTEL DIEU   (France)

^b INSTITUT CURIE   (France)

^c UNIVERSITÉ PIERRE MENDÈS FRANCE   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f Paris Descartes University ^*  (France)

Author keywords

brain imaging; brain perfusion single photon computed tomography; cardiovascular risk factors; dysexecutive syndrome; functional imaging; vascular cognitive impairment; vascular dementia

Indexed keywords

ACETAZOLAMIDE; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; ANTIOXIDANT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLINESTERASE INHIBITOR; CYANOCOBALAMIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FOLIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; VITAMIN D;

ALCOHOLISM; BRAIN INFARCTION; BRAIN PERFUSION; BRAIN SCINTISCANNING; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; COGNITIVE DEFECT; COGNITIVE RESERVE; CONGESTIVE HEART FAILURE; CORONARY FLOW RESERVE; DEMENTIA; DEPRESSION; DIABETES MELLITUS; DIET THERAPY; DOUBLE BLIND PROCEDURE; DYSAUTONOMIA; EDUCATIONAL STATUS; FOLIC ACID DEFICIENCY; FUNCTIONAL NEUROIMAGING; HEART ATRIUM FIBRILLATION; HEART FAILURE; HORMONE SUBSTITUTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPOTENSION; LACUNAR STROKE; LEUKOARAIOSIS; LIMIT OF QUANTITATION; META ANALYSIS (TOPIC); MIDDLE AGED; MONOTHERAPY; MORPHOLOGY; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; ORTHOSTATIC HYPOTENSION; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SMOKING; SOCIAL ASPECT; STENOSIS; SUBCORTICAL ISCHEMIC VASCULAR DEMENTIA; VASCULAR COGNITIVE IMPAIRMENT; VITAMIN D DEFICIENCY;

ACETAZOLAMIDE; BRAIN; CARBONIC ANHYDRASE INHIBITORS; CEREBROVASCULAR DISORDERS; COGNITION DISORDERS; HUMANS; MAGNETIC RESONANCE IMAGING; RISK FACTORS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84860839357     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e328351d583     Document Type: Review

References (76)

1. Bruandet A, Richard F, Bombois S, Maurage CA, Deramecourt V, Lebert F, et al. Alzheimer disease with cerebrovascular disease and vascular dementia: clinical features and course compared with Alzheimer disease. J Neurol Neurosurg Psychiatry 2009; 80:133-139.
2. Rojas-Fernandez CH, Moorhouse P. Current concepts in vascular cognitive impairment and pharmacotherapeutic implications. Ann Pharmacother 2009; 43:1310-1323.
3. Guidetti D, Casali B, Mazzei RL, Dotti MT. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Clin Exp Hypertens 2006; 28 (3-4):271-277. (Pubitemid 44178499)
4. Nicoll JA, Yamada M, Frackowiak J, Mazur-Kolecka B, Weller RO. Cerebral amyloid angiopathy plays a direct role in the pathogenesis of Alzheimer's disease. pro-CAA position statement. Neurobiol Aging 2004; 25:589-597, discussion 603-584. (Pubitemid 38686478)
5. Barker WW, Luis CA, Kashuba A, Luis M, Harwood DG, Loewenstein D, et al. Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the State of Florida Brain Bank. Alzheimer Dis Assoc Disord 2002; 16:203-212. (Pubitemid 35434796)
6. Hebert R, Lindsay J, Verreault R, Rockwood K, Hill G, Dubois MF. Vascular dementia: incidence and risk factors in the Canadian study of health and aging. Stroke 2000; 31:1487-1493. (Pubitemid 30437492)
7. Roman GC. Vascular dementia may be the most common form of dementia in the elderly. J Neurol Sci 2002; 203-204:7-10. (Pubitemid 35287368)
8. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007; 6:734-746. (Pubitemid 47058377)
9. Roman GC. Brain hypoperfusion: a critical factor in vascular dementia. Neurol Res 2004; 26:454-458. (Pubitemid 38879227)
10. Brayne C. The elephant in the room-healthy brains in later life, epidemiology and public health. Nat Rev Neurosci 2007; 8:233-239.
11. Farid K, Caillat-Vigneron N, Sibon I. Is brain SPECT useful in degenerative dementia diagnosis? J Comput Assist Tomogr 2011; 35:1-3.
12. Villemagne VL, Ong K, Mulligan RS, Holl G, Pejoska S, Jones G, et al. Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias. J Nucl Med 2011; 52:1210-1217.
13. Bohnen NI, Djang DS, Herholz K, Anzai Y, Minoshima S. Effectiveness and safety of 18 F-FDG PET in the evaluation of dementia: a review of the recent literature. J Nucl Med 2012; 53:59-71.
14. Reiman EM. Focus on Alzheimer's disease and related disorders. J Clin Psychiatry 2005; 66:816-817. (Pubitemid 41032820)
15. Hanyu H, Sato T, Shimizu S, Kanetaka H, Iwamoto T, Koizumi K. The effect of education on rCBF changes in Alzheimer's disease: a longitudinal SPECT study. Eur J Nucl Med Mol Imaging 2008; 35:2182-2190.
16. Andaluz N, Choutka O, Vagal A, Strunk R, Zuccarello M. Patient selection for revascularization procedures in adult Moyamoya disease based on dynamic perfusion computerized tomography with acetazolamide challenge (PCTA). Neurosurg Rev 2010; 33:225-232, discussion 232-223.
17. Iida H, Nakagawara J, Hayashida K, Fukushima K, Watabe H, Koshino K, et al. Multicenter evaluation of a standardized protocol for rest and acetazolamide cerebral blood flow assessment using a quantitative SPECT reconstruction program and split-dose 123I-iodoamphetamine. J Nucl Med 2010; 51:1624-1631.
18. Farid K, Meissner WG, Samier-Foubert A, Barret O, Menegon P, Rouanet F, et al. Normal cerebrovascular reactivity in stroke-like migraine attacks after radiation therapy syndrome. Clin Nucl Med 2010; 35:583-585.
19. Farid K, Renou P, Laffite M, Couffinhal T, Allard M, Fernandez P, et al. Postprandial recurrent hemiplegia. Clin Nucl Med 2010; 35:80-82.
20. O'Brien JT, Erkinjuntti T, Reisberg B, Roman G, Sawada T, Pantoni L, et al. Vascular cognitive impairment. Lancet Neurol 2003; 2:89-98. (Pubitemid 37443329)
21. Firbank MJ, Allan LM, Burton EJ, Barber R, O'Brien JT, Kalaria RN. Neuroimaging predictors of death and dementia in a cohort of older stroke survivors. J Neurol Neurosurg Psychiatry 2011[Epub ahead of print].
22. Sachdev PS, Brodaty H, Valenzuela MJ, Lorentz L, Looi JC, Berman K, et al. Clinical determinants of dementia and mild cognitive impairment following ischaemic stroke: the Sydney Stroke Study. Dement Geriatr Cogn Disord 2006; 21 (5-6):275-283. (Pubitemid 43735670)
23. Hoffmann M, Schmitt F, Bromley E. Vascular cognitive syndromes: relation to stroke etiology and topography. Acta Neurol Scand 2009; 120:161-169.
24. Liu Y, Karonen JO, Nuutinen J,Vanninen E, Kuikka JT, Vanninen RL. Crossed cerebellar diaschisis in acute ischemic stroke: a study with serial SPECT and MRI. J Cereb Blood Flow Metab 2007; 27:1724-1732. (Pubitemid 47476095)
25. Roman GC, Erkinjuntti T, Wallin A, Pantoni L, Chui HC. Subcortical ischaemic vascular dementia. Lancet Neurol 2002; 1:426-436. (Pubitemid 37159153)
26. Ferrer I. Cognitive impairment of vascular origin: neuropathology of cognitive impairment of vascular origin. J Neurol Sci 2010; 299 (1-2):139-149.
27. Cummings JL. Vascular subcortical dementias: clinical aspects. Dementia 1994; 5 (3-4):177-180. (Pubitemid 24151542)
28. Stewart JT. The frontal/subcortical dementias: common dementing illnesses associated with prominent and disturbing behavioral changes. Geriatrics 2006; 61:23-27. (Pubitemid 44267073)
29. Bonelli RM, Cummings JL. Frontal-subcortical dementias. Neurologist 2008; 14:100-107. (Pubitemid 351366942)
30. Uh J, Yezhuvath U, Cheng Y, Lu H. In vivo vascular hallmarks of diffuse leukoaraiosis. J Magn Reson Imaging 2010; 32:184-190.
31. Cohen RA, Paul RH, Zawacki TM, Sethi M, Ott BR, Moser DJ, et al. Single photon emission computed tomography, magnetic resonance imaging hyperintensity, and cognitive impairments in patients with vascular dementia. J Neuroimaging 2001; 11:253-260. (Pubitemid 32625270)
32. Bronge L, Wahlund LO. White matter changes in dementia: does radiology matter? Br J Radiol 2007; 80 Spec. No. 2:S115-S120. (Pubitemid 351799338)
33. De Leeuw FE, de Groot JC, Achten E, Oudkerk M, Ramos LM, Heijboer R, et al. Prevalence of cerebral white matter lesions in elderly people: a population based magnetic resonance imaging study. The Rotterdam Scan Study. J Neurol Neurosurg Psychiatry 2001; 70:9-14. (Pubitemid 32096113)
34. Bartzokis G. Age-related myelin breakdown: a developmental model of cognitive decline and Alzheimer's disease. Neurobiol Aging 2004; 25:5-18 author reply 49-62. (Pubitemid 37522186)
35. Schmidtke K, Hull M. Cerebral small vessel disease: how does it progress? J Neurol Sci 2005; 229-230:13-20. (Pubitemid 40341559)
36. Fernando MS, Ince PG. Vascular pathologies and cognition in a population-based cohort of elderly people. J Neurol Sci 2004; 226 (1-2):13-17. (Pubitemid 39505399)
37. Wright CB, Festa JR, Paik MC, Schmiedigen A, Brown TR, Yoshita M, et al. White matter hyperintensities and subclinical infarction: associations with psychomotor speed and cognitive flexibility. Stroke 2008; 39:800-805. (Pubitemid 351619538)
38. Benisty S, Gouw AA, Porcher R, Madureira S, Hernandez K, Poggesi A, et al. Location of lacunar infarcts correlates with cognition in a sample of non-disabled subjects with age-related white-matter changes: the LADIS study. J Neurol Neurosurg Psychiatry 2009; 80:478-483.
39. Spilt A, Goekoop R, Westendorp RG, Blauw GJ, de Craen AJ, van Buchem MA. Not all age-related white matter hyperintensities are the same: a magnetization transfer imaging study. Am J Neuroradiol 2006; 27: 1964-1968. (Pubitemid 44556518)
40. Mendez MF, Shapira JS, McMurtray A, Licht E. Preliminary findings: behavioral worsening on donepezil in patients with frontotemporal dementia. Am J Geriatr Psychiatry 2007; 15:84-87. (Pubitemid 46106094)
41. Takahashi W, Takagi S, Ide M, Shohtsu A, Shinohara Y. Reduced cerebral glucose metabolism in subjects with incidental hyperintensities on magnetic resonance imaging. J Neurol Sci 2000; 176:21-27. (Pubitemid 30365006)
42. Yang DW, Kim BS, Park JK, Kim SY, Kim EN, Sohn HS. Analysis of cerebral blood flow of subcortical vascular dementia with single photon emission computed tomography: adaptation of statistical parametric mapping. J Neurol Sci 2002; 203-204:199-205.
43. Sabri O, Hellwig D, Schreckenberger M, Cremerius U, Schneider R, Kaiser HJ, et al. Correlation of neuropsychological, morphological and functional (regional cerebral blood flow and glucose utilization) findings in cerebral microangiopathy. J Nucl Med 1998; 39:147-154. (Pubitemid 28063188)
44. Kitagawa K, Oku N, Kimura Y, Yagita Y, Sakaguchi M, Hatazawa J, et al. Relationship between cerebral blood flow and later cognitive decline in hypertensive patients with cerebral small vessel disease. Hypertens Res 2009; 32:816-820.
45. Jimenez-Bonilla JF, Quirce R, Hernandez A, Vallina NK, Guede C, Banzo I, et al. Assessment of cerebral perfusion and cerebrovascular reserve in insulin-dependent diabetic patients without central neurological symptoms by means of 99mTc-HMPAO SPET with acetazolamide. Eur J Nucl Med 2001; 28:1647-1655. (Pubitemid 33036107)
46. Tomura N, Sasaki K, Kidani H, Nishii T, Yasuda K, Ishiyama K, et al. Reduced perfusion reserve in leukoaraiosis demonstrated using acetazolamide challenge 123I-IMP SPECT. J Comput Assist Tomogr 2007; 31:884-887. (Pubitemid 350196931)
47. Fazekas F, Kleinert R, Roob G, Kleinert G, Kapeller P, Schmidt R, et al. Histopathologic analysis of foci of signal loss on gradient-echo T2*-weighted MR images in patients with spontaneous intracerebral hemorrhage: evidence of microangiopathy-related microbleeds. Am J Neuroradiol 1999; 20:637-642. (Pubitemid 30429021)
48. Hermier M, Nighoghossian N, Derex L, Berthezene Y, Blanc-Lasserre K, Trouillas P, et al. MRI of acute post-ischemic cerebral hemorrhage in stroke patients: diagnosis with T2*-weighted gradient-echo sequences. Neuroradiology 2001; 43:809-815. (Pubitemid 32976413)
49. Chung YA, O JH, Kim JY, Kim KJ, Ahn KJ. Hypoperfusion and ischemia in cerebral amyloid angiopathy documented by 99mTc-ECD brain perfusion SPECT. J Nucl Med 2009; 50:1969-1974.
50. Klijn CJ, Kappelle LJ. Haemodynamic stroke: clinical features, prognosis, and management. Lancet Neurol 2010; 9:1008-1017.
51. Vernieri F, Pasqualetti P, Passarelli F, Rossini PM, Silvestrini M. Outcome of carotid artery occlusion is predicted by cerebrovascular reactivity. Stroke 1999; 30:593-598. (Pubitemid 29115397)
52. Yonas H, Smith HA, Durham SR, Pentheny SL, Johnson DW. Increased stroke risk predicted by compromised cerebral blood flow reactivity. J Neurosurg 1993; 79:483-489. (Pubitemid 23289802)
53. Stephan BC, Brayne C. Vascular factors and prevention of dementia. Int Rev Psychiatry 2008; 20:344-356.
54. Middleton LE, Yaffe K. Promising strategies for the prevention of dementia. Arch Neurol 2009; 66:1210-1215.
55. Efimova IY, Efimova NY, Triss SV, Lishmanov YB. Brain perfusion and cognitive function changes in hypertensive patients. Hypertens Res 2008; 31:673-678. (Pubitemid 351772858)
56. Struijker Boudier HA, le Noble JL, Huijberts MS, le Noble FA, van Essen H. The microcirculation and hypertension. J Hypertens Suppl 1992; 10:S147-S156. (Pubitemid 23045181)
57. Skoog I, Lernfelt B, Landahl S, Palmertz B, Andreasson LA, Nilsson L, et al. 15-year longitudinal study of blood pressure and dementia. Lancet 1996; 347:1141-1145. (Pubitemid 126512042)
58. Terborg C, Gora F, Weiller C, Rother J. Reduced vasomotor reactivity in cerebral microangiopathy: a study with near-infrared spectroscopy and transcranial Doppler sonography. Stroke 2000; 31:924-929. (Pubitemid 30198440)
59. Schroeter ML, Bucheler MM, Preul C, Scheid R, Schmiedel O, Guthke T, et al. Spontaneous slow hemodynamic oscillations are impaired in cerebral microangiopathy. J Cereb Blood Flow Metab 2005; 25:1675-1684. (Pubitemid 41683178)
60. Hund-Georgiadis M, Zysset S, Naganawa S, Norris DG, Von Cramon DY. Determination of cerebrovascular reactivity by means of FMRI signal changes in cerebral microangiopathy: a correlation with morphological abnormalities. Cerebrovasc Dis 2003; 16:158-165. (Pubitemid 36693847)
61. Richard E, Ligthart SA, Moll van Charante EP, van Gool WA. Vascular risk factors and dementia-towards prevention strategies. Neth J Med 2010; 68:284-290.
62. Scarmeas N, Luchsinger JA, Schupf N, Brickman AM, Cosentino S, Tang MX, et al. Physical activity, diet, and risk of Alzheimer disease. JAMA 2009; 302:627-637.
63. Fratiglioni L, Paillard-Borg S, Winblad B. An active and socially integrated lifestyle in late life might protect against dementia. Lancet Neurol 2004; 3:343-353. (Pubitemid 38648855)
64. Alagiakrishnan K, McCracken P, Feldman H. Treating vascular risk factors and maintaining vascular health: is this the way towards successful cognitive ageing and preventing cognitive decline? Postgrad Med J 2006; 82:101-105. (Pubitemid 43266138)
65. Forette F, Seux ML, Staessen JA, Thijs L, Birkenhager WH, Babarskiene MR, et al. Prevention of dementia in randomised double-blind placebo-controlled systolic hypertension in Europe (Syst-Eur) trial. Lancet 1998; 352:1347-1351. (Pubitemid 28510916)
66. Guo Z, Fratiglioni L, Zhu L, Fastbom J, Winblad B, Viitanen M. Occurrence and progression of dementia in a community population aged 75 years and older: relationship of antihypertensive medication use. Arch Neurol 1999; 56:991-996. (Pubitemid 29374817)
67. Starr JM, Whalley LJ, Deary IJ. The effects of antihypertensive treatment on cognitive function: results from the HOPE study. J Am Geriatr Soc 1996; 44:411-415. (Pubitemid 26115555)
68. Jacobson EJ. Hypertension. Update on use of angiotensin II receptor blockers. Geriatrics 2001; 56:20-21, 25-28.
69. Poon IO. Effects of antihypertensive drug treatment on the risk of dementia and cognitive impairment. Pharmacotherapy 2008; 28:366-375. (Pubitemid 351328909)
70. Peters R, Beckett N, Forette F, Tuomilehto J, Clarke R, Ritchie C, et al. Incident dementia and blood pressure lowering in the hypertension in the very elderly trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurol 2008; 7:683-689.
71. Zandi PP, Sparks DL, Khachaturian AS, Tschanz J, Norton M, Steinberg M, et al. Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. Arch Gen Psychiatry 2005; 62:217-224. (Pubitemid 40189139)
72. Pomponi M, Di Gioia A, Bria P, Pomponi MF. Fatty aspirin: a new perspective in the prevention of dementia of Alzheimer's type? Curr Alzheimer Res 2008; 5:422-431.
73. Meyer JS, Rogers RL, McClintic K, Mortel KF, Lotfi J. Randomized clinical trial of daily aspirin therapy in multi-infarct dementia. A pilot study. J Am Geriatr Soc 1989; 37:549-555. (Pubitemid 19135928)
74. Price JF, Stewart MC, Deary IJ, Murray GD, Sandercock P, Butcher I, et al. Low dose aspirin and cognitive function in middle aged to elderly adults: randomised controlled trial. BMJ 2008; 337:a1198.
75. Roman GC, Kalaria RN. Vascular determinants of cholinergic deficits in Alzheimer disease and vascular dementia. Neurobiol Aging 2006; 27:1769-1785. (Pubitemid 44572575)
76. Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet 2002; 359:1283-1290. (Pubitemid 34310633)